Developer docs
API playgroundTry for free, no card

Search company profiles

Starton Therapeutics

Full company profile

uuid0000cs8

Namestring
Starton Therapeutics
Legal namestring
Starton USA Inc.
Websiteurl
startontx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Starton Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Paramus, New Jersey (with a Canadian parent incorporated in British Columbia). The company develops proprietary continuous delivery formulations of FDA-approved active ingredients, with its lead program STAR-LLD delivering lenalidomide — the active in Bristol-Myers Squibb's Revlimid — via subcutaneous infusion, oral controlled release, or transdermal patch. The platform's design intent is to flatten pharmacokinetic exposure, reducing Cmax by more than 90% and AUC by approximately 57% versus conventional oral dosing while sustaining plasma concentrations above the minimum effective threshold (~0.04-0.1 uM/L) for 24 hours. Preclinical multiple myeloma models showed 80% tumor shrinkage with STAR-LLD versus five-fold tumor growth on daily lenalidomide, and the Phase 1b study in relapsed/refractory multiple myeloma produced a 100% objective response rate (1 CR, 5 PR) across six patients with no grade >2 drug-related hematologic toxicity.

The company's go-to-market is structured around clinical development and eventual pharmaceutical commercialization rather than current sales. STAR-LLD-SC (subcutaneous) is in Phase 2a for relapsed/refractory multiple myeloma (first patient dosed February 2026); STAR-LLD-OCR (oral controlled release) is in development for CLL and high-risk myeloma through a partnership with Bend Bioscience; and a transdermal variant is protected by a 2024 Notice of Allowance. Provisional patent applications extend the platform into CAR-T and bispecific antibody combinations. Manufacturing and preclinical work is supported by Bend Bioscience (oral CR CDMO), Primetech Corporation (iPRECIO programmable pumps for translational studies), and the Sargon Site Network for multi-site Phase 2a conduct. Industry engagement runs through AACR, Biotech Showcase, Longwood Healthcare Leaders, and IR partner LifeSci Advisors.

Starton is pre-revenue, with operating capital historically raised through SEC Form D exempt securities offerings totaling roughly $10.7M between 2018 and 2024 across the US and Canada. Future revenue, if any, will be generated through pharmaceutical product sales and/or licensing after regulatory approval of STAR-LLD in hematologic malignancies; pricing has not been disclosed and no partnership license economics are public. The leadership team is anchored by Chairman and CEO Pedro Lichtinger (former Pfizer President of Global Primary Care and Europe), alongside a CFO (Scott Kahn) and CMO (Jamie Oliver, Pharm.D.) with prior IND/NDA experience, supported by an 11-50 person organization and a board including independent members drawn from biopharma, finance, and law.

Short descriptiontext

Starton Therapeutics is a clinical-stage biotechnology company developing proprietary continuous-delivery formulations of lenalidomide (STAR-LLD) administered subcutaneously, orally, or transdermally to improve efficacy and tolerability in multiple myeloma and other hematologic malignancies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParamus, United States
HQ citystring
Paramus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous drug delivery, cancer therapeutics, multiple myeloma treatment, drug formulation platform, subcutaneous infusion therapy
Industry1 code
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Hematologic Cancer Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotechnology company developing proprietary continuous delivery formulations of approved drugs. Revenue will be generated through pharmaceutical product sales upon regulatory approval for STAR-LLD in multiple myeloma and CLL indications.

startontx.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Starton Therapeutics is a clinical-stage biotechnology company that develops proprietary continuous-delivery formulations of FDA-approved active ingredients, with lead product STAR-LLD delivering lenalidomide continuously via subcutaneous infusion, oral controlled-release tablets, or transdermal patches. The technology targets hematologic malignancies, primarily multiple myeloma and chronic lymphocytic leukemia, with the goal of replacing and expanding standard-of-care oncology regimens through improved pharmacokinetics. The company partners with CDMOs and runs US-based clinical trials to advance its pipeline toward commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 100% objective response rate (1 CR, 5 PRs) in Phase 1b study of 6 relapsed/refractory MM patients with no grade >2 drug-related hematologic toxicity
+3 more records
Product overview1 text field

Starton Therapeutics is a clinical-stage biotechnology company developing a proprietary continuous delivery technology platform to transform FDA-approved active ingredients into improved therapies. The core product is STAR-LLD (Continuous Low-Dose Lenalidomide), a formulation of lenalidomide delivered continuously via subcutaneous infusion, oral controlled release tablets, or transdermal patches. STAR-LLD-SC is in Phase 2a trials for relapsed/refractory multiple myeloma, STAR-LLD-OCR is in development for CLL and high-risk MM (in partnership with Bend Bioscience), and STAR-LLD Transdermal is in preclinical/development stages. The platform technology aims to replace and expand standard-of-care products by maintaining optimal pharmacokinetic profiles 24 hours a day, potentially improving efficacy and tolerability for cancer patients.

Product and service4 records
1STAR-LLD (Continuous Low-Dose Lenalidomide)
CategoryContinuous-delivery oncology drug (platform product)
Description

Proprietary continuous-delivery reformulation of the FDA-approved immunomodulatory drug lenalidomide, designed to maintain therapeutic plasma levels for 24 hours while reducing Cmax by more than 90% and AUC by approximately 57% compared to standard oral dosing. Indicated for relapsed/refractory multiple myeloma and chronic lymphocytic leukemia, and is the platform product across Starton's three delivery formats.

2STAR-LLD-SC (Subcutaneous)
CategoryContinuous-delivery subcutaneous oncology drug
Description

STAR-LLD administered via continuous subcutaneous infusion using ambulatory pumps, with greater than 91% bioavailability. Currently in Phase 1b/Phase 2a clinical trials for relapsed/refractory multiple myeloma and explored in combination with CAR-T cell therapies.

3STAR-LLD-OCR (Oral Controlled Release)
CategoryContinuous-delivery oral oncology drug
Description

STAR-LLD delivered as an oral controlled-release tablet formulation, in development for chronic lymphocytic leukemia and high-risk relapsed/refractory multiple myeloma. Co-developed with Bend Bioscience for formulation, scale-up, and commercial manufacturing.

4STAR-LLD Transdermal
CategoryContinuous-delivery transdermal oncology drug
Description

STAR-LLD delivered via transdermal patch system for continuous low-dose administration. Patent-protected delivery route achieving blood levels equivalent to 8-18 hours post-oral dose using 10-75% of the standard daily oral dose, intended to provide a non-invasive outpatient-friendly option.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

Clinical trial site network partnership for Phase 2a study of STAR-LLD in multiple myeloma. Study expanded from 2 to 6 investigational sites across the US including Gabrail Cancer & Research Center (Canton, OH), Regional Medical Oncology Center (Wilson, NC), and new sites in Wisconsin, Florida, California, and Arizona.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-24
Description

Strategic development agreement with Bend Bioscience, a CDMO and pharmaceutical services partner, for development of oral sustained release dosage form of STAR-LLD. Bend provides drug delivery R&D support, formulation optimization, manufacturing process development, and will lead scale-up and commercial manufacturing efforts. The collaboration leverages Bend's expertise in controlled release formulation and clinical/commercial manufacturing of solid oral dosage forms.

Strategic tierMinorTypeOthers
Description

Investor relations and communications partner providing IR contact support including Alex Starr, Managing Director.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1Bristol-Myers Squibb
TypeBroad incumbent
Description

Marketer of Revlimid (lenalidomide), the standard-of-care multiple myeloma therapy that STAR-LLD is designed to replace or supplement. Most directly comparable incumbent in the target indication and the primary competitive benchmark for efficacy, safety, and pricing.

TypeDirect peer
Description

Drug-delivery platform company (ENHANZE recombinant human hyaluronidase) that licenses subcutaneous delivery technology to large pharma, enabling reformulation of approved IV drugs. Closely comparable business model—platform technology used to create improved formulations of established APIs.

TypeDirect peer
Description

Specialty pharma built around reformulating and improving delivery of approved molecules (Xtampza ER, Nucynta, Belbuca). Comparable strategy of taking established APIs and creating differentiated, often abuse-deterrent or controlled-release products for better clinical outcomes.

TypeDirect peer
Description

Clinical-stage oncology/hematology company commercializing XPO1 inhibitor selinexor (Xpovio) in multiple myeloma. Closely comparable clinical-stage biotech competing in the same MM space with a novel mechanism intended to overcome treatment resistance.

TypeDirect peer
Description

Clinical-stage hematology biotech developing imetelstat (a first-in-class telomerase inhibitor) for lower-risk MDS and myelofibrosis. Comparable clinical-stage profile, target hematology indications, and reliance on platform technology to address unmet needs in blood cancers.

TypeDirect peer
Description

Clinical-stage biotech developing CAR-T cell therapies (e.g., anito-cel) for multiple myeloma and other hematologic malignancies. Comparable clinical-stage hematology peer and one of the named competitors in the BCMA-targeted MM space where Starton's CAR-T combination patents are positioned.

TypeEmerging player
Description

Clinical-to-commercial biotech behind Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T for multiple myeloma commercialized with Johnson & Johnson. Relevant emerging player because Starton's CAR-T + STAR-LLD combination patents target exactly the patient population Carvykti addresses.

TypeDirect peer
Description

Generic pharmaceutical manufacturer with an authorized generic lenalidomide franchise. Directly comparable as a competing supplier of lenalidomide-based therapy and a key pricing/reimbursement benchmark for STAR-LLD's commercial opportunity.

TypeBroad incumbent
Description

Sells DARZALEX (daratumumab) and is Legend Biotech's CAR-T partner for Carvykti, anchoring the standard of care in multiple myeloma. Relevant broad incumbent competitor whose entrenched position STAR-LLD and its combination programs must contend with.

TypeBroad incumbent
Description

Large oncology pharma where Starton CEO Pedro Lichtinger spent 16 years (President of Global Primary Care and Europe). Relevant broad incumbent and potential strategic partner/acquirer given Lichtinger's deep relationships and Pfizer's hematology portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Starton Therapeutics

Hematologic Cancer Therapeuticsstartontx.com

Starton Therapeutics is a clinical-stage biotechnology company developing proprietary continuous-delivery formulations of lenalidomide (STAR-LLD) administered subcutaneously, orally, or transdermally to improve efficacy and tolerability in multiple myeloma and other hematologic malignancies.

What Starton Therapeutics does

Starton Therapeutics is a privately held, clinical-stage biotechnology company founded in 2017 and headquartered in Paramus, New Jersey (with a Canadian parent incorporated in British Columbia). The company develops proprietary continuous delivery formulations of FDA-approved active ingredients, with its lead program STAR-LLD delivering lenalidomide — the active in Bristol-Myers Squibb's Revlimid — via subcutaneous infusion, oral controlled release, or transdermal patch. The platform's design intent is to flatten pharmacokinetic exposure, reducing Cmax by more than 90% and AUC by approximately 57% versus conventional oral dosing while sustaining plasma concentrations above the minimum effective threshold (~0.04-0.1 uM/L) for 24 hours. Preclinical multiple myeloma models showed 80% tumor shrinkage with STAR-LLD versus five-fold tumor growth on daily lenalidomide, and the Phase 1b study in relapsed/refractory multiple myeloma produced a 100% objective response rate (1 CR, 5 PR) across six patients with no grade >2 drug-related hematologic toxicity.

The company's go-to-market is structured around clinical development and eventual pharmaceutical commercialization rather than current sales. STAR-LLD-SC (subcutaneous) is in Phase 2a for relapsed/refractory multiple myeloma (first patient dosed February 2026); STAR-LLD-OCR (oral controlled release) is in development for CLL and high-risk myeloma through a partnership with Bend Bioscience; and a transdermal variant is protected by a 2024 Notice of Allowance. Provisional patent applications extend the platform into CAR-T and bispecific antibody combinations. Manufacturing and preclinical work is supported by Bend Bioscience (oral CR CDMO), Primetech Corporation (iPRECIO programmable pumps for translational studies), and the Sargon Site Network for multi-site Phase 2a conduct. Industry engagement runs through AACR, Biotech Showcase, Longwood Healthcare Leaders, and IR partner LifeSci Advisors.

Starton is pre-revenue, with operating capital historically raised through SEC Form D exempt securities offerings totaling roughly $10.7M between 2018 and 2024 across the US and Canada. Future revenue, if any, will be generated through pharmaceutical product sales and/or licensing after regulatory approval of STAR-LLD in hematologic malignancies; pricing has not been disclosed and no partnership license economics are public. The leadership team is anchored by Chairman and CEO Pedro Lichtinger (former Pfizer President of Global Primary Care and Europe), alongside a CFO (Scott Kahn) and CMO (Jamie Oliver, Pharm.D.) with prior IND/NDA experience, supported by an 11-50 person organization and a board including independent members drawn from biopharma, finance, and law.

Starton Therapeutics firmographics

Firmographics
Name
Starton Therapeutics
Legal name
Starton USA Inc.
Website
https://startontx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Starton Therapeutics is a clinical-stage biotechnology company developing proprietary continuous-delivery formulations of lenalidomide (STAR-LLD) administered subcutaneously, orally, or transdermally to improve efficacy and tolerability in multiple myeloma and other hematologic malignancies.
Ownership category
akta.pro rank

Starton Therapeutics industry classification

Industry
Product category
Hematologic Cancer Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Continuous drug delivery
  • Cancer therapeutics
  • Multiple myeloma treatment
  • Drug formulation platform
  • Subcutaneous infusion therapy

Where Starton Therapeutics is headquartered

Location

Headquarters

HQ city
Paramus
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Starton Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing proprietary continuous delivery formulations of approved drugs. Revenue will be generated through pharmaceutical product sales upon regulatory approval for STAR-LLD in multiple myeloma and CLL indications.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Starton Therapeutics product offering

Product offering

Core offering

Starton Therapeutics is a clinical-stage biotechnology company that develops proprietary continuous-delivery formulations of FDA-approved active ingredients, with lead product STAR-LLD delivering lenalidomide continuously via subcutaneous infusion, oral controlled-release tablets, or transdermal patches. The technology targets hematologic malignancies, primarily multiple myeloma and chronic lymphocytic leukemia, with the goal of replacing and expanding standard-of-care oncology regimens through improved pharmacokinetics. The company partners with CDMOs and runs US-based clinical trials to advance its pipeline toward commercialization.

Product overview

Starton Therapeutics is a clinical-stage biotechnology company developing a proprietary continuous delivery technology platform to transform FDA-approved active ingredients into improved therapies. The core product is STAR-LLD (Continuous Low-Dose Lenalidomide), a formulation of lenalidomide delivered continuously via subcutaneous infusion, oral controlled release tablets, or transdermal patches. STAR-LLD-SC is in Phase 2a trials for relapsed/refractory multiple myeloma, STAR-LLD-OCR is in development for CLL and high-risk MM (in partnership with Bend Bioscience), and STAR-LLD Transdermal is in preclinical/development stages. The platform technology aims to replace and expand standard-of-care products by maintaining optimal pharmacokinetic profiles 24 hours a day, potentially improving efficacy and tolerability for cancer patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • STAR-LLD (Continuous Low-Dose Lenalidomide) Proprietary continuous-delivery reformulation of the FDA-approved immunomodulatory drug lenalidomide, designed to maintain therapeutic plasma levels for 24 hours while reducing Cmax by more than 90% and AUC by approximately 57% compared to standard oral dosing. Indicated for relapsed/refractory multiple myeloma and chronic lymphocytic leukemia, and is the platform product across Starton's three delivery formats.
  • STAR-LLD-SC (Subcutaneous) STAR-LLD administered via continuous subcutaneous infusion using ambulatory pumps, with greater than 91% bioavailability. Currently in Phase 1b/Phase 2a clinical trials for relapsed/refractory multiple myeloma and explored in combination with CAR-T cell therapies.
  • STAR-LLD-OCR (Oral Controlled Release) STAR-LLD delivered as an oral controlled-release tablet formulation, in development for chronic lymphocytic leukemia and high-risk relapsed/refractory multiple myeloma. Co-developed with Bend Bioscience for formulation, scale-up, and commercial manufacturing.
  • STAR-LLD Transdermal STAR-LLD delivered via transdermal patch system for continuous low-dose administration. Patent-protected delivery route achieving blood levels equivalent to 8-18 hours post-oral dose using 10-75% of the standard daily oral dose, intended to provide a non-invasive outpatient-friendly option.

Quantifiable outcome

  • 100% objective response rate (1 CR, 5 PRs) in Phase 1b study of 6 relapsed/refractory MM patients with no grade >2 drug-related hematologic toxicity
  • +3 more outcomes

Companies that use Starton Therapeutics

Customer profile

Segments2 records

Ideal customer profiles3 records

Starton Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Starton Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Sargon Site NetworkcoreStrategic or Co-development Partner · 19 February 2026Clinical trial site network partnership for Phase 2a study of STAR-LLD in multiple myeloma. Study expanded from 2 to 6 investigational sites across the US including Gabrail Cancer & Research Center (Canton, OH), Regional Medical Oncology Center (Wilson, NC), and new sites in Wisconsin, Florida, California, and Arizona.
  • Bend BiosciencecoreStrategic or Co-development Partner · 24 June 2025Strategic development agreement with Bend Bioscience, a CDMO and pharmaceutical services partner, for development of oral sustained release dosage form of STAR-LLD. Bend provides drug delivery R&D support, formulation optimization, manufacturing process development, and will lead scale-up and commercial manufacturing efforts. The collaboration leverages Bend's expertise in controlled release formulation and clinical/commercial manufacturing of solid oral dosage forms.
  • LifeSci AdvisorsminorOthersInvestor relations and communications partner providing IR contact support including Alex Starr, Managing Director.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Starton Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Bristol-Myers Squibb: Marketer of Revlimid (lenalidomide), the standard-of-care multiple myeloma therapy that STAR-LLD is designed to replace or supplement. Most directly comparable incumbent in the target indication and the primary competitive benchmark for efficacy, safety, and pricing.
  • Johnson & Johnson: Sells DARZALEX (daratumumab) and is Legend Biotech's CAR-T partner for Carvykti, anchoring the standard of care in multiple myeloma. Relevant broad incumbent competitor whose entrenched position STAR-LLD and its combination programs must contend with.
  • Pfizer: Large oncology pharma where Starton CEO Pedro Lichtinger spent 16 years (President of Global Primary Care and Europe). Relevant broad incumbent and potential strategic partner/acquirer given Lichtinger's deep relationships and Pfizer's hematology portfolio.

Direct peers

  • Halozyme Therapeutics: Drug-delivery platform company (ENHANZE recombinant human hyaluronidase) that licenses subcutaneous delivery technology to large pharma, enabling reformulation of approved IV drugs. Closely comparable business model—platform technology used to create improved formulations of established APIs.
  • Collegium Pharmaceutical: Specialty pharma built around reformulating and improving delivery of approved molecules (Xtampza ER, Nucynta, Belbuca). Comparable strategy of taking established APIs and creating differentiated, often abuse-deterrent or controlled-release products for better clinical outcomes.
  • Karyopharm Therapeutics: Clinical-stage oncology/hematology company commercializing XPO1 inhibitor selinexor (Xpovio) in multiple myeloma. Closely comparable clinical-stage biotech competing in the same MM space with a novel mechanism intended to overcome treatment resistance.
  • Geron Corporation: Clinical-stage hematology biotech developing imetelstat (a first-in-class telomerase inhibitor) for lower-risk MDS and myelofibrosis. Comparable clinical-stage profile, target hematology indications, and reliance on platform technology to address unmet needs in blood cancers.
  • Arcellx: Clinical-stage biotech developing CAR-T cell therapies (e.g., anito-cel) for multiple myeloma and other hematologic malignancies. Comparable clinical-stage hematology peer and one of the named competitors in the BCMA-targeted MM space where Starton's CAR-T combination patents are positioned.
  • Amneal Pharmaceuticals: Generic pharmaceutical manufacturer with an authorized generic lenalidomide franchise. Directly comparable as a competing supplier of lenalidomide-based therapy and a key pricing/reimbursement benchmark for STAR-LLD's commercial opportunity.

Emerging players

  • Legend Biotech: Clinical-to-commercial biotech behind Carvykti (ciltacabtagene autoleucel), a BCMA-directed CAR-T for multiple myeloma commercialized with Johnson & Johnson. Relevant emerging player because Starton's CAR-T + STAR-LLD combination patents target exactly the patient population Carvykti addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Starton Therapeutics social profiles

Digital presence

Starton Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Starton Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Starton Therapeutics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Starton Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Starton Therapeutics

What does Starton Therapeutics do?

Starton Therapeutics is a clinical-stage biotechnology company that develops proprietary continuous-delivery formulations of FDA-approved active ingredients, with lead product STAR-LLD delivering lenalidomide continuously via subcutaneous infusion, oral controlled-release tablets, or transdermal patches. The technology targets hematologic malignancies, primarily multiple myeloma and chronic lymphocytic leukemia, with the goal of replacing and expanding standard-of-care oncology regimens through improved pharmacokinetics. The company partners with CDMOs and runs US-based clinical trials to advance its pipeline toward commercialization.

Is Starton Therapeutics a public or private company?

Starton Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Starton Therapeutics founded?

Starton Therapeutics was founded in 2017. It employs 11 to 50 people.

Where is Starton Therapeutics based?

Starton Therapeutics is headquartered in Paramus, United States, in the North America region.

How does Starton Therapeutics make money?

One revenue line is on record: pharmaceutical Product Development and Commercialization.

Who are Starton Therapeutics's main competitors?

Broad incumbents on record are Bristol-Myers Squibb, Johnson & Johnson and Pfizer. Direct peers are Halozyme Therapeutics, Collegium Pharmaceutical, Karyopharm Therapeutics, Geron Corporation, Arcellx and Amneal Pharmaceuticals. Legend Biotech is listed as an emerging player.

Does Starton Therapeutics have an API?

No public API is recorded for Starton Therapeutics.

What industry is Starton Therapeutics in?

Starton Therapeutics's product category is Hematologic Cancer Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogStarton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaStarton Therapeutics signed a clinical trial agreement with Stanford School of Medicine to evaluate STAR-LLD, a continuous delivery lenalidomide, combined with a novel CAR-T therapy for relapsed or refractory multiple myeloma. The study will assess safety and preliminary efficacy, with data expected to support a Phase 2 IND. The company anticipates presenting the results for publication.FinancialContent Business PageStarton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaStarton Therapeutics signed a clinical trial agreement with Stanford School of Medicine to evaluate STAR-LLD, a continuous-delivery lenalidomide, combined with a novel CAR-T therapy for relapsed or refractory multiple myeloma. The study will assess safety and preliminary efficacy, with data expected to support a Phase 2 IND. The company anticipates presenting results for publication.Business Wire BlogStarton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO 2026Starton Therapeutics CEO Pedro Lichtinger will join a panel at the Longwood Healthcare Leaders Boston CEO 2026 meeting on November 3, 2026, at the Mandarin Oriental in Boston. The panel, titled 'Building Global BioPharmas,' brings together biopharmaceutical leaders for off-the-record discussions on drug development and strategic partnerships.Business Wire BlogStarton Therapeutics to Participate in Spotlight Panel at BioFuture 2026Starton Therapeutics announced that Chief Medical Officer Dr. Jamie Oliver will speak at BioFuture 2026, held Oct. 27-28 in New York. The panel will discuss technologies shaping life sciences, including oncology, CNS, metabolic disease, and diagnostics.FinancialContent Business PageStarton Therapeutics to Participate in Spotlight Panel at BioFuture 2026Starton Therapeutics announced that Chief Medical Officer Dr. Jamie Oliver will participate as a panelist at BioFuture 2026, held Oct. 27-28 in New York. The panel, titled 'BioFuture Now: Breakthroughs Shaping the Next Era of Biopharma,' will discuss technologies across oncology, CNS, metabolic disease, and diagnostics.BioSpaceStarton Therapeutics Appoints Experienced Finance Executive Saleem Elmasri, CPA, as Chief Financial OfficerStarton Therapeutics appointed Saleem Elmasri, CPA, as Chief Financial Officer, succeeding Scott Kahn. Elmasri brings 20 years of finance and consulting experience, including public CFO roles, and will support the company's upcoming IPO.GlobeNewswireStarton Therapeutics Files Patent Applications for the Use of CAR-T Cell Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of LenalidStarton Therapeutics filed patent applications for combining its continuous low-dose lenalidomide (STAR-LLD) with CAR-T cell therapies. Preclinical data showed STAR-LLD shrank tumors by 80% with 100% response, while daily lenalidomide gave 20% response. The company aims to improve CAR-T expansion and durability while reducing toxicity.GlobeNewswireStarton Therapeutics Files Patent Application for the Use of Multi-Specific Antibody-Based Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formStarton Therapeutics filed a patent application for combining its continuous low-dose lenalidomide (STAR-LLD) with multi-specific antibodies for cancer treatment. Phase 1b data showed STAR-LLD improved tolerability with no grade >2 hematologic toxicity, and preclinical studies reported 80% tumor shrinkage and 100% overall response rate.GlobeNewswireStarton Therapeutics Announces Dosing of First Patient in Phase 2a Study Evaluating STAR-LLD for the Treatment of Multiple MyelomaStarton Therapeutics dosed the first patient in its Phase 2a study of STAR-LLD for relapsed/refractory multiple myeloma. The randomized trial compares three doses of continuous subcutaneous infusion with oral lenalidomide, enrolling 24 patients with an option to expand to 69. Enrollment completion is estimated in the first half of 2027.GlobeNewswireStarton Therapeutics to Present at Biotech Showcase 2026Starton Therapeutics CEO Pedro Lichtinger will present at Biotech Showcase 2026 in San Francisco on January 12, 2026. The company's STAR-LLD continuous lenalidomide showed an 80% tumor shrinkage in preclinical studies and all six patients in a Phase 1b study achieved an objective response.